Credit: Alvogen, Inc. Fentanyl is an opioid agonist indicated for the management of severe or persistent pain in opioid-tolerant patients. At this time, Alvogen Inc has received 1 serious adverse ...
MIRAMAR, Fla., Feb. 17, 2025 /PRNewswire/ -- Aveva Drug Delivery systems (A DifGen company), a leader in transdermal drug delivery systems based out of Miramar - Florida is proud to announce the ...
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl ...
NDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials needed prior to submission. AVERSA™ Fentanyl incorporates Nutriband's Aversa™ ...
Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing Nutriband working to complete the commercial scale-up prior to ...
The U.S. Food and Drug Administration announced last week that a pharmaceutical company is removing a fentanyl patch from patient and pharmacy access because of a packaging flaw that has resulted in ...
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it ...
Delhi, March 17, 2025 (GLOBE NEWSWIRE) -- Global Transdermal Patch Market Opportunity, Patch Dosage, Price & Clinical Trials Insight 2030 Report Highlights & Findings: The global market for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results